secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001628280-24-023179
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q1 net loss $0.05/share, cash $26.4M; OCU400 Phase 3 underway
--------------------------------------------------------------------

- Net loss $0.05/share for Q1 2024 vs $0.08 loss in Q1 2023; total operating expenses $13.2M, down 29% YoY.
- Cash and cash equivalents $26.4M at March 31, 2024, versus $39.5M at December 31, 2023.
- OCU400 Phase 3 liMeliGhT trial cleared by FDA; dosing begins Q2 2024; EMA supports MAA submission.
- OCU410 (dAMD) cohort 2 dosing complete; Phase 2 expansion expected Q3 2024. OCU410ST cohort 2 enrollment initiated.
- NeoCart GMP facility renovated; Phase 3 contingent on funding. OCU500 IND planned mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/ocgn-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-023179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer